From Bench to Bedside in Emerging Therapies for Gynecological Malignancies: A Narrative Review

Abstract

Gynecological malignancies, including cervical, endometrial, and ovarian cancers, pose significant global health challenges due to their increasing incidence and limitations in conventional treatments. Current therapeutic approaches, such as surgery, chemotherapy, and radiation, often face obstacles like multidrug resistance, tumor recurrence, and adverse side effects. In response, emerging therapies—including targeted therapy, immunotherapy, and gene therapy—are reshaping treatment paradigms. Precision medicine, leveraging Poly ADP-ribose Polymerase (PARP) and Vascular Endothelial Growth Factor (VEGF) inhibitors, enhances therapeutic efficacy, while immune checkpoint inhibitors and vaccine-based therapies offer promising immunotherapeutic strategies. Additionally, advancements in nanotechnology and gene therapy, including Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) based approaches and nanoparticle-mediated drug delivery, provide novel treatment modalities. Despite these innovations, translational challenges persist, necessitating further research into clinical applications and personalized treatment strategies. This review highlights the latest advancements in emerging therapies for gynecological malignancies, emphasizing their potential to improve patient outcomes and address existing treatment limitations.

Introduction

Background on Gynecological Malignancies

Gynecological malignancies encompass a variety of cancers affecting the female reproductive system, including cervical, endometrial, and ovarian cancer. Among these, cervical cancer is noted as the most common type of gynecological cancer. ¹ Endometrial cancer, in particular, stands out as the most prevalent gynecological cancer, although it faces challenges in terms of care and policy changes. ² The genetics of breast and gynecologic cancers play a significant role in hereditary cancer syndromes such as BReast CAncer gene (BRCA1/BRCA2) and Lynch syndrome. ³ Menopause age has been identified as a factor influencing the development of major gynecologic cancers. ⁴ Real-world drug treatment models have focused on novel targeted drugs for gynecological reproductive cancers, due to their common occurrence. ⁵ The frequency of these gynecological cancers, has been on the rise, highlighting the need for further research and treatment options. ⁶ These cancers, which include ovarian, vulvar, vaginal, endometrial, and cervical cancers, contribute significantly to the global burden of disease. ⁷ Gynecologic cancers, pose a considerable burden on healthcare systems worldwide. ⁸ Nanoparticles have shown promise in the treatment of gynecologic cancers, offering new strategies and prospects for improved outcomes. ⁹ Screening programs, such as HPV testing recommended by the World Health Organization and the Canadian Partnership Against Cancer, play a crucial role in early detection and prevention of cervical cancer. ¹⁰ Overall, gynecological malignancies present a complex and challenging landscape, necessitating ongoing research and advancements in treatment modalities to address their global burden.

Current Treatment Challenges

Gynecological malignancies pose significant challenges in treatment due to the limitations of conventional therapies like surgery, chemotherapy, and radiation. While these treatments have been the cornerstone of cancer management, their efficacy is often hindered by factors such as multidrug resistance, tumor recurrence, and severe side effects. In the realm of cancer research, innovative therapeutic approaches are being explored to address these challenges. For instance, the use of stimulus-responsive hydrogels for targeted cancer therapy has gained attention. These hydrogels can respond to various stimuli, including biological, chemical, and physical cues, offering a promising avenue for more precise and effective treatment strategies. ¹¹ Moreover, the emergence of biogenic nanoparticles synthesized from plant extracts presents a sustainable and eco-friendly approach to breast cancer therapeutics. These nanoparticles have shown significant toxicity against breast cancer cells while sparing healthy ones, highlighting their potential as a novel treatment modality. ¹² In the context of gynecological malignancies, surgery-based radiation-free multimodality treatments have been explored for locally advanced cervical cancer. This approach aims to provide effective treatment while minimizing the adverse effects associated with conventional therapies like radiation. ¹³ Furthermore, the integration of therapeutics and diagnostics in cancer treatment, known as cancer theragnostics, offers a personalized approach to cancer management. By utilizing imaging agents, biomarkers, and other diagnostic tools, theragnostics can tailor treatment strategies to individual patients, enhancing the efficacy of existing therapies. ¹⁴ Overall, the current landscape of gynecological malignancy treatment underscores the need for novel and targeted approaches to overcome the limitations of conventional therapies. By exploring innovative strategies such as stimulus-responsive hydrogels, biogenic nanoparticles, and surgery-based multimodality treatments, researchers aim to improve patient outcomes and quality of life in the face of these challenging diseases.

Rationale for Emerging Therapies

Gynecological malignancies pose a significant health burden, with ovarian cancer being a major concern due to its high mortality rate. Targeted therapies have emerged as a promising approach to improve treatment outcomes for gynecologic cancers. Studies have shown that targeted therapies have changed the treatment landscape for these malignancies, with new options and updates being continuously explored. ¹⁵ For example, PARP inhibitors have shown efficacy in the treatment of gynecologic cancers, particularly in cases with existing DNA damage-repair deficiencies. ¹⁶ Additionally, the use of ozone-oxygen therapy has been proposed as a preventive strategy for HPV-related cancers of the lower gynecological tract, highlighting the importance of innovative approaches in cancer prevention. ¹⁷ The emerging burden of ovarian cancer, especially in low- and middle-income countries, has prompted the need for de-escalation of targeted therapy to address challenges and improve outcomes. ¹⁸ Furthermore, the incorporation of new treatment strategies, such as osteoclast-targeted therapies, has shown promise in the management of bone metastases in various types of cancer, including gynecological malignancies. ¹⁹ These emerging therapies offer new avenues for the prophylaxis and management of acute and chronic complications associated with gynecologic cancers, emphasizing the importance of staying updated on the latest advancements in the field. ²⁰

A paradigm change away from conventional cytotoxic therapies and toward more individualized and preventative oncology is reflected in the incorporation of novel targeted techniques. Even though these treatments have a lot of potential, they need to be strategically adjusted for clinical use, particularly in settings with limited resources. To ensure that cutting-edge treatments can reach larger patient populations without escalating health inequities, it is crucial to strike a balance between innovation and accessibility.

Methods

Literature Search Strategy

For this narrative review, a comprehensive literature search was conducted using electronic databases, including PubMed, Scopus, Web of Science, and Embase, to identify relevant studies on emerging therapies for gynecological malignancies. ²¹ The search strategy incorporated a combination of MeSH terms and free-text keywords, such as “gynecological malignancies,” “ovarian cancer,” “cervical cancer,” “endometrial cancer,” “targeted therapy,” “immunotherapy,” “precision medicine,” and “clinical trials”. ²² Studies published in peer-reviewed journals within the past 5 years were prioritized to ensure the inclusion of the most recent advancements. ²³ Additional references were considered for historical context. Inclusion criteria encompassed original research, clinical trials, meta-analyses, and high-quality review articles focusing on translational and clinical advancements in treatment. ²⁴ Studies not published in English, case reports, and those with limited clinical relevance were excluded. ²⁵

This review maintains scientific trustworthiness while reflecting the current state of the subject thanks to the careful selection of recent, high-quality literature. The approach facilitates a thorough yet critical evaluation of new treatments by emphasizing peer-reviewed research and clinically meaningful data. This approach strengthens the review’s legitimacy and offers a strong basis for further study and clinical judgment.

Types of Emerging Therapies Reviewed

Emerging therapies for gynecological malignancies can be broadly classified into targeted therapy, immunotherapy, and gene therapy, each offering novel approaches to improve treatment outcomes. ²⁴ Targeted therapies, such as PARP inhibitors (eg, olaparib and niraparib), focus on specific molecular alterations in cancer cells, leading to improved efficacy with reduced toxicity. ²⁴ Immunotherapy, including immune checkpoint inhibitors like pembrolizumab and nivolumab, has shown promising results by enhancing the body’s immune response against tumors. ²⁵ Additionally, gene therapy strategies, such as CRISPR/Cas9-based genome editing and oncolytic viral therapy, aim to correct genetic defects or selectively eliminate cancer cells. ²² These advancements signify a paradigm shift in gynecological cancer management, moving from conventional treatments to more precision-based and personalized medicine approaches. ²¹

A fundamental shift in oncology practice is represented by the diversification of therapeutic approaches. Despite the distinct benefits that each class of therapy offers, incorporating them into treatment plans necessitates a sophisticated comprehension of tumor biology, patient-specific variables, and health system capacities. For these treatments to reach their full potential in enhancing the survival and quality of life of patients with gynecological malignancies, ongoing clinical validation and fair application are essential.

Results (Findings From Existing Studies)

Targeted Therapies and Precision Medicine

Targeted therapies and precision medicine have revolutionized the field of cancer treatment by focusing on specific molecular targets to improve patient outcomes. Advances in PARP inhibitors, VEGF inhibitors, and hormonal therapies have shown promising results in various types of cancer. PARP inhibitors have emerged as a significant treatment option in cancer therapy, with several FDA-approved drugs available for clinical use. ²⁶ These inhibitors target specific DNA repair mechanisms in cancer cells, leading to cell death and tumor regression. In addition, the use of PARP inhibitors in combination with other therapies, such as immune checkpoint inhibitors, has shown potential in enhancing therapeutic outcomes. ²⁷ VEGF inhibitors, which target the vascular endothelial growth factor pathway, have also shown promise in cancer treatment. ²⁸ Clinical trials are underway to evaluate the efficacy of VEGF signaling inhibitors in advanced cancer cases. These targeted therapies aim to disrupt the tumor microenvironment and inhibit angiogenesis, ultimately leading to tumor regression and improved patient outcomes. Hormonal therapies, particularly in hormone receptor-positive breast cancer, have been a cornerstone in precision medicine. ²⁹ The combination of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy has shown significant benefits in the first-line treatment of estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer. Additionally, the use of endocrine drugs in Hormone Receptor Positive (HR+) breast cancer has been crucial in inhibiting tumor recurrence, proliferation, and metastasis. ³⁰

Antibody-Drug Conjugates (ADCs)

ADCs have emerged as a promising therapeutic modality in gynecological oncology by delivering cytotoxic agents directly to tumor cells, minimizing off-target toxicity. Folate receptor-alpha (FRα) is highly expressed in ovarian cancer, making FRα-targeted ADCs such as mirvetuximab soravtansine a notable advancement, which has shown encouraging results in recurrent, platinum-resistant ovarian cancer patients. ²⁶ Additionally, Trophoblast Cell Surface Antigen 2 (TROP2)-targeted ADCs like sacituzumab govitecan have demonstrated efficacy in endometrial and cervical cancers by targeting trophoblast cell-surface antigen 2, a protein frequently overexpressed in epithelial malignancies. ²⁶ CDH6 (Cadherin-6) ADCs are also under clinical evaluation due to their expression in ovarian and endometrial tumors, offering another targeted option. ²⁶ These ADCs represent a promising approach by combining the specificity of monoclonal antibodies with the potency of chemotherapy.

Immunotherapy in Gynecological Cancers

Immunotherapy has emerged as a promising approach in the treatment of various cancers, including gynecological cancers. The use of checkpoint inhibitors, such as programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors, and vaccine-based therapies has shown potential in enhancing the immune response against cancer cells. Studies have highlighted the role of different proteins and pathways in immune evasion and response to immunotherapy in cancer. Yu et al ³¹ investigated the correlation between integrin αvβ6 and PD-L1 expression in colon cancer tissues, suggesting a potential role of αvβ6 in immune escape through the regulation of PD-L1. Ho et al ³² discussed the cross-talk between Raf Kinase Inhibitor Protein and PD-L1 expressions in cancer, emphasizing the importance of understanding additional immunoregulatory mechanisms in cancer patients. Wu et al ³³ reviewed the progress of PD-1/PD-L1 inhibitors in colorectal cancer, providing insights into potential treatment options for early and middle-stage disease. In gynecological cancers, Wang et al ³⁴ developed an Immune-Associated Gene Prognostic Index specific for cervical carcinoma, highlighting the significance of immune-related biomarkers in predicting patient outcomes and guiding immunotherapy strategies. Wada et al ³⁵ discussed the efficacy of immunotherapy combinations in endometrial cancer, showcasing ongoing trials comparing chemotherapy with immunotherapy combinations. Furthermore, Tempora et al ³⁶ proposed a combinatorial strategy involving Endoplasmic Reticulum Aminopeptidase 1(ERAP1) silencing and entinostat therapy to enhance the immunogenicity of neuroblastoma and overcome resistance to PD-1 therapy. Zhang et al ³⁷ introduced a novel hexapeptide capable of downregulating PD-L1 and self-assembling into a hydrogel, offering a potential alternative to antibody-based PD-1/PD-L1 inhibitors.

These new immunotherapeutic approaches focus on particular cellular and molecular mechanisms that contribute to tumor immune evasion. Checkpoint inhibitors, for example, reactivate tired T cells by blocking PD-1/PD-L1 interactions; ERAP1 silencing modifies antigen processing to increase tumor immunogenicity; and new medicines, like as hexapeptides, directly affect immune checkpoint expression. These treatments aid in the restoration of efficient antitumor immunity by interfering with these specific immunoregulatory circuits, providing a more individualized and mechanism-based method of treating gynecological cancers.

Gene Therapy and Nanotechnology-Based Treatments

Nanotechnology has shown significant promise in the field of cancer treatment, particularly in the development of personalized and targeted therapies based on the unique genetic and molecular profile of an individual’s tumor. ³⁸ Nanomedicine-enabled chemotherapy-based treatments have demonstrated synergetic effects in cancer therapy. ³⁹ Emerging modalities in cancer treatment include small molecule targeted agents, antibody-drug conjugates, cell-based therapies, and gene therapy. ⁴⁰ Nanotechnology-based medicinal products have been explored for controllable photodynamic cancer therapy. ⁴¹ In the realm of gynecological malignancies, nanoparticles have been utilized for drug and gene delivery, including the application of paclitaxel in modern oncology. ⁴² Furthermore, RNA-based therapies, such as Short interfering RNA (SiRNA) therapeutics, have shown promise in gene silencing for cancer treatment. ⁴³ Oligonucleotide-based therapies, including interfering RNAs, have gained a central role in advancing cancer treatments. ⁴⁴ The intersection of nanotechnology and gene therapy holds great potential for the treatment of gynecological malignancies. Recent developments in cancer nanotechnology have revolutionized cancer immunotherapy, with a focus on RNA-based vaccines. ⁴⁵ Additionally, the combination of gene therapy with nanomedicine for targeted therapeutic interventions has shown promise in the treatment of various cancers, including gynecological malignancies. ⁴⁶ While the potential of CRISPR-based cancer therapies is promising, further investigation is needed to address potential side effects. ⁴⁷

Human papillomavirus (HPV) and ovarian cancer are both significant public health concerns, with current treatments showing limited effectiveness in advanced or persistent cases. RNA-based therapeutics, especially mRNA vaccines, are emerging as a promising strategy to address these challenges. ⁴⁸ In HPV-related cancers, mRNA vaccines targeting viral oncoproteins like E6 and E7 have shown the ability to stimulate strong immune responses and are currently being tested in clinical trials with encouraging results. ⁴⁹ Similarly, in ovarian cancer, RNA-based approaches such as siRNAs and mRNA vaccines are being explored to silence oncogenes, overcome drug resistance, and activate the immune system against tumor cells. ⁵⁰ Novel delivery platforms, including nano-based systems, are helping to improve RNA stability and minimize off-target effects. Despite challenges related to delivery and immune responses, continued advancements in RNA-based therapeutics offer great potential for improving cancer treatment outcomes and expanding the scope of personalized medicine.

Ovarian cancer often presents at an advanced stage with poor survival rates and resistance to standard therapies. Theranostic agents, which combine diagnosis and treatment, offer a promising approach by enabling early detection and targeted therapy. Advances in molecular imaging and biomarker research are key to improving outcomes through more precise and effective management. ⁵¹

Discussion and Conclusion

Clinical Implications and Translational Challenges

Gynecological malignancies present unique challenges in both clinical practice and translational research. Recent studies have highlighted the potential of utilizing organoids to create immune microenvironments for gynecological tumors, offering new insights into fundamental and translational investigations. ⁵² Nano-immunotherapy has also emerged as a promising advancement in the field, although challenges remain in translating these innovations from the lab to real-world applications. ⁵³ Nanoparticles have shown promise in providing targeted therapy with low side effects for gynecological malignancies, paving the way for clinical theragnostics. ⁹ Fumarate Hydratase Deficiency (FHD) has been identified as a rare disorder with implications for cancer risk, shedding light on the clinical and oncological implications in gynecology.54 Additionally, exploring treatment options in cancer, including T cell exhaustion and precision medicine, has highlighted the importance of translational value in clinical practice and the challenges that lie ahead.^40,55 Approaches to prevention of gynecological malignancies have been a focus of translational and clinical research, with ongoing clinical trials assessing the efficacy of treatments. ⁵⁶ The complexity of Homologous Recombination Deficiency (HRD) assessment in ovarian cancer poses a significant challenge in clinical practice, prompting discussions on the role of homologous recombination deficiency testing and its clinical implications. ⁵⁷ Liquid biopsy has also emerged as a valuable tool in cancer research, with implications for gynecologic cancer patients and the potential for future translational applications. ⁵⁸

Emerging therapeutics have particular advantages and difficulties. Organoids are good at simulating tumors, however they have scalability issues. Although it is challenging to produce, nano-immunotherapy provides tailored treatment with reduced toxicity. Although biocompatibility is an issue, theragnostic nanoparticles combine diagnostic and treatment. Rare patients benefit from FHD research, but its applications are limited. T cell treatments include the possibility of adverse effects but may restore immunity. Personalized care is supported by HRD testing, while availability and expense are barriers. Although non-invasive, liquid biopsies require more precision for early detection.

Overcoming Drug Resistance in Gynecological Malignancies

Drug resistance, especially to platinum-based chemotherapy and PARP inhibitors, remains a significant challenge in treating gynecologic cancers. Several mechanisms, including restoration of homologous recombination, drug efflux pump overexpression, and tumor microenvironment alterations, contribute to resistance development. ⁴⁰ In response, novel strategies are being explored. Combining PARP inhibitors with antiangiogenic agents or immune checkpoint inhibitors has shown promise in overcoming resistance. ²⁷ Additionally, Ataxia Telangiectasia and Rad3-related (ATR) kinase inhibitors and WEE1 kinase inhibitors are under investigation to target DNA damage response pathways in PARP-resistant setting. ⁴⁰ Epigenetic modulators, such as histone deacetylase inhibitors (HDACi), are also being evaluated for their potential to re-sensitize resistant tumors. The integration of these approaches into clinical protocols may enhance the durability of responses and prolong progression-free survival in resistant gynecologic cancers.

Future Directions and Research Gaps

Despite significant advancements in emerging therapies for gynecological malignancies, critical research gaps remain that must be addressed to optimize clinical outcomes and ensure equitable access to care.

First, the cost-effectiveness and scalability of advanced therapies, such as gene editing, CAR-T cell therapy, and mRNA-based vaccines, remain poorly defined. These high-cost interventions raise concerns about accessibility, especially in low- and middle-income countries (LMICs). ⁵⁹ Future studies should explore:

• What is the cost-effectiveness of gene and cell therapies for various gynecological malignancies across different healthcare settings?

• How can delivery platforms be adapted to reduce costs and improve scalability in resource-limited regions?

Second, there is a lack of robust criteria for optimal patient selection for novel immunotherapies and targeted therapies. While molecular profiling has enabled some stratification, heterogeneity in tumor microenvironments and immune responses limits predictive accuracy. ⁶⁰ Therefore, future research should investigate:

• Which biomarkers most accurately predict response to immunotherapies in ovarian, cervical, and endometrial cancers?

• Can AI-based integrative models improve patient stratification for personalized therapies?

Third, the long-term safety and efficacy profiles of mRNA platforms and gene-editing tools like CRISPR-Cas9 are not fully understood. Although initial clinical results are promising, comprehensive longitudinal data are lacking. ⁶¹ Critical questions include:

• What are the long-term immunological, oncogenic, or off-target effects of mRNA- and CRISPR-based therapies in gynecologic oncology?

• How can surveillance frameworks be developed to monitor delayed adverse events in treated patients?

Fourth, integration of emerging therapies into existing treatment protocols remains a challenge. Synergistic combinations with chemotherapy, radiotherapy, or hormonal treatments require careful evaluation. ⁶² Future trials should assess:

• Which therapeutic combinations yield the highest synergistic benefits with minimal toxicity?

• How can sequencing and timing of interventions be optimized for different cancer subtypes?

Finally, patient-reported outcomes (PROs), quality of life (QoL), and psychosocial impacts of novel therapies have received insufficient attention. While clinical endpoints like progression-free survival are essential, understanding the patient experience is equally critical. ⁶³ Key questions include:

• How do emerging therapies affect long-term QoL in gynecological cancer survivors?

• What psychosocial support mechanisms are needed for patients undergoing complex, experimental treatments?

Addressing these gaps through interdisciplinary, multicenter, and globally inclusive research efforts will be vital for translating scientific advances into sustainable clinical practice.